BioRegenx, Inc Financials
This page shows BioRegenx, Inc (BRGX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
BioRegenx, Inc has an operating margin of -972.7%, meaning the company retains $-973 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -99.9% the prior year.
BioRegenx, Inc's revenue declined 31.4% year-over-year, from $3.4M to $2.3M. This contraction results in a growth score of 0/100.
BioRegenx, Inc's current ratio of 0.08 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 0/100, which could limit financial flexibility.
While BioRegenx, Inc generated -$324K in operating cash flow, capex of $189K consumed most of it, leaving -$514K in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
BioRegenx, Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, BioRegenx, Inc generates $0.01 in operating cash flow (-$324K OCF vs -$23.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
BioRegenx, Inc earns $-3429.2 in operating income for every $1 of interest expense (-$22.8M vs $7K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
BioRegenx, Inc generated $2.3M in revenue in fiscal year 2024. This represents a decrease of 31.4% from the prior year.
BioRegenx, Inc's EBITDA was -$20.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 503.3% from the prior year.
BioRegenx, Inc generated -$514K in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 66.1% from the prior year.
BioRegenx, Inc reported -$23.1M in net income in fiscal year 2024. This represents a decrease of 540.4% from the prior year.
BioRegenx, Inc earned $-0.02 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 100.0% from the prior year.
BioRegenx, Inc held $58K in cash against $255K in long-term debt as of fiscal year 2024.
BioRegenx, Inc had 957M shares outstanding in fiscal year 2024. This represents an increase of 245.8% from the prior year.
BioRegenx, Inc's gross margin was 70.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 3.1 percentage points from the prior year.
BioRegenx, Inc's operating margin was -972.7% in fiscal year 2024, reflecting core business profitability. This is down 872.8 percentage points from the prior year.
BioRegenx, Inc's net profit margin was -985.2% in fiscal year 2024, showing the share of revenue converted to profit. This is down 879.6 percentage points from the prior year.
BioRegenx, Inc invested $0 in research and development in fiscal year 2024. This represents a decrease of 100.0% from the prior year.
BioRegenx, Inc invested $189K in capex in fiscal year 2024, funding long-term assets and infrastructure.
BRGX Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $508K+13.9% | $446K-13.4% | $515K+11.9% | $460K-22.7% | $596K-18.8% | $734K+33.6% | $550K-18.9% | $678K |
| Cost of Revenue | $81K-13.0% | $94K-14.3% | $109K-20.8% | $138K+20.4% | $114K-56.7% | $264K+59.7% | $165K-44.9% | $300K |
| Gross Profit | $426K+21.0% | $352K-13.2% | $406K+25.8% | $323K-33.0% | $482K+2.5% | $470K+22.3% | $384K+1.6% | $378K |
| R&D Expenses | $0 | $0 | $0+100.0% | -$33K | $0-100.0% | $8K-70.6% | $26K+66.0% | $15K |
| SG&A Expenses | $433K-5.3% | $457K-22.6% | $590K-27.0% | $809K+242.3% | $236K-83.1% | $1.4M-59.0% | $3.4M+589.3% | $495K |
| Operating Income | -$8K+92.1% | -$107K+44.3% | -$193K+98.9% | -$18.3M-5496.2% | -$327K+68.5% | -$1.0M+66.2% | -$3.1M-1355.6% | -$212K |
| Interest Expense | $72K+1.4% | $71K+626.2% | $10K+107.7% | -$127K-288.4% | $68K+1.8% | $66K | $0-100.0% | $286K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
| Net Income | -$81K+54.8% | -$178K+33.2% | -$267K+98.5% | -$18.4M-4560.0% | -$395K+64.3% | -$1.1M+64.9% | -$3.2M-1127.8% | -$257K |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | N/A | $0.00 | $0.00 | $0.00 | N/A |
BRGX Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.2M+1.5% | $1.2M+138.4% | $483K-5.1% | $509K-97.1% | $17.4M-3.0% | $17.9M-3.9% | $18.6M+2050.7% | $866K |
| Current Assets | $273K+9.4% | $250K-15.2% | $294K-4.4% | $308K-17.0% | $371K+13.8% | $326K-32.8% | $485K-25.6% | $653K |
| Cash & Equivalents | $47K+1.1% | $46K-44.4% | $84K+43.2% | $58K-16.7% | $70K+22.1% | $57K-49.7% | $114K-9.0% | $125K |
| Inventory | $109K-18.5% | $134K-4.4% | $140K+26.4% | $111K-30.0% | $159K+10.3% | $144K-32.5% | $213K-1.9% | $218K |
| Accounts Receivable | $63K+196.5% | $21K+89.3% | $11K-25.6% | $15K-22.9% | $19K+77.7% | $11K-2.1% | $11K-89.3% | $105K |
| Goodwill | N/A | N/A | N/A | N/A | $7.1M0.0% | $7.1M0.0% | $7.1M | $0 |
| Total Liabilities | $4.8M+0.2% | $4.8M+18.9% | $4.0M+4.0% | $3.9M+2.3% | $3.8M+3.6% | $3.7M+3.8% | $3.5M+20.3% | $2.9M |
| Current Liabilities | $3.9M+0.2% | $3.9M+3.7% | $3.8M+4.2% | $3.6M+3.3% | $3.5M+2.9% | $3.4M+1.0% | $3.4M+21.4% | $2.8M |
| Long-Term Debt | N/A | N/A | N/A | $255K | N/A | N/A | $550K | $0 |
| Total Equity | -$3.6M+0.2% | -$3.7M-2.7% | -$3.6M-5.3% | -$3.4M-124.9% | $13.6M-4.6% | $14.2M-5.7% | $15.1M+828.3% | -$2.1M |
| Retained Earnings | -$36.1M-0.2% | -$36.0M-0.5% | -$35.8M-0.8% | -$35.6M-107.2% | -$17.2M-2.4% | -$16.8M-7.1% | -$15.7M-25.2% | -$12.5M |
BRGX Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$72K-2332.9% | $3K-91.5% | $38K+431.8% | -$11K+63.6% | -$31K+82.4% | -$177K-70.1% | -$104K+57.6% | -$246K |
| Capital Expenditures | $6K | $0 | $0 | $0 | $0 | $0-100.0% | $189K | $0 |
| Free Cash Flow | -$78K-2520.1% | $3K-91.5% | $38K+431.8% | -$11K+63.6% | -$31K+82.4% | -$177K+39.6% | -$294K-19.5% | -$246K |
| Investing Cash Flow | -$6K+88.0% | -$50K | $0-100.0% | $3K | $0 | $0+100.0% | -$191K+4.4% | -$199K |
| Financing Cash Flow | $71K+321.0% | $17K+261.5% | -$10K-50.0% | -$7K-115.0% | $46K-61.3% | $120K-57.5% | $283K-45.0% | $513K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BRGX Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 84.0%+4.9pp | 79.0%+0.2pp | 78.8%+8.7pp | 70.1%-10.7pp | 80.8%+16.8pp | 64.0%-5.9pp | 69.9%+14.1pp | 55.8% |
| Operating Margin | -1.7%+22.4pp | -24.1%+13.3pp | -37.4%+3940.3pp | -3977.7%-3922.8pp | -54.9%+86.8pp | -141.7%+418.7pp | -560.4%-529.2pp | -31.2% |
| Net Margin | -15.9%+24.1pp | -40.0%+11.8pp | -51.8%+3944.1pp | -3995.9%-3929.6pp | -66.3%+84.4pp | -150.7%+423.0pp | -573.7%-535.8pp | -37.9% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -6.9%+8.6pp | -15.5%+39.8pp | -55.3%+3563.1pp | -3618.4%-3616.1pp | -2.3%+3.9pp | -6.2%+10.8pp | -16.9%+12.7pp | -29.7% |
| Current Ratio | 0.070.0 | 0.06-0.0 | 0.080.0 | 0.08-0.0 | 0.11+0.0 | 0.10-0.0 | 0.14-0.1 | 0.23 |
| Debt-to-Equity | -1.320.0 | -1.31-0.2 | -1.14-1.1 | -0.08-0.4 | 0.28+0.0 | 0.26+0.2 | 0.04+0.0 | 0.00 |
| FCF Margin | -15.3%-16.0pp | 0.7%-6.6pp | 7.3%+9.8pp | -2.5%+2.8pp | -5.2%+18.9pp | -24.2%+29.3pp | -53.4%-17.2pp | -36.2% |
Note: Shareholder equity is negative (-$3.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.08), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is BioRegenx, Inc's annual revenue?
BioRegenx, Inc (BRGX) reported $2.3M in total revenue for fiscal year 2024. This represents a -31.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is BioRegenx, Inc's revenue growing?
BioRegenx, Inc (BRGX) revenue declined by 31.4% year-over-year, from $3.4M to $2.3M in fiscal year 2024.
Is BioRegenx, Inc profitable?
No, BioRegenx, Inc (BRGX) reported a net income of -$23.1M in fiscal year 2024, with a net profit margin of -985.2%.
What is BioRegenx, Inc's earnings per share (EPS)?
BioRegenx, Inc (BRGX) reported diluted earnings per share of $-0.02 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is BioRegenx, Inc's EBITDA?
BioRegenx, Inc (BRGX) had EBITDA of -$20.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does BioRegenx, Inc have?
As of fiscal year 2024, BioRegenx, Inc (BRGX) had $58K in cash and equivalents against $255K in long-term debt.
What is BioRegenx, Inc's gross margin?
BioRegenx, Inc (BRGX) had a gross margin of 70.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is BioRegenx, Inc's operating margin?
BioRegenx, Inc (BRGX) had an operating margin of -972.7% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is BioRegenx, Inc's net profit margin?
BioRegenx, Inc (BRGX) had a net profit margin of -985.2% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is BioRegenx, Inc's free cash flow?
BioRegenx, Inc (BRGX) generated -$514K in free cash flow during fiscal year 2024. This represents a 66.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BioRegenx, Inc's operating cash flow?
BioRegenx, Inc (BRGX) generated -$324K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are BioRegenx, Inc's total assets?
BioRegenx, Inc (BRGX) had $509K in total assets as of fiscal year 2024, including both current and long-term assets.
What are BioRegenx, Inc's capital expenditures?
BioRegenx, Inc (BRGX) invested $189K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How many shares does BioRegenx, Inc have outstanding?
BioRegenx, Inc (BRGX) had 957M shares outstanding as of fiscal year 2024.
What is BioRegenx, Inc's current ratio?
BioRegenx, Inc (BRGX) had a current ratio of 0.08 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is BioRegenx, Inc's debt-to-equity ratio?
BioRegenx, Inc (BRGX) had a debt-to-equity ratio of -0.08 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BioRegenx, Inc's return on assets (ROA)?
BioRegenx, Inc (BRGX) had a return on assets of -4533.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is BioRegenx, Inc's cash runway?
Based on fiscal year 2024 data, BioRegenx, Inc (BRGX) had $58K in cash against an annual operating cash burn of $324K. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is BioRegenx, Inc's debt-to-equity ratio negative or unusual?
BioRegenx, Inc (BRGX) has negative shareholder equity of -$3.4M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is BioRegenx, Inc's Piotroski F-Score?
BioRegenx, Inc (BRGX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BioRegenx, Inc's earnings high quality?
BioRegenx, Inc (BRGX) has an earnings quality ratio of 0.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BioRegenx, Inc cover its interest payments?
BioRegenx, Inc (BRGX) has an interest coverage ratio of -3429.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is BioRegenx, Inc?
BioRegenx, Inc (BRGX) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.